中国大陆慢性皮肤黏膜念珠菌病回顾性分析(1980—2020年)

摘要/Abstract

摘要： 目的总结与探讨中国大陆慢性皮肤黏膜念珠菌病（chronic mucocutaneous candidiasis，CMC）的病因、流行病学、临床特征及诊疗情况。方法检索分析中国知网、万方、维普及PubMed等数据库中1980-2020年中国大陆确诊为慢性皮肤黏膜念珠菌病的相关文献资料。结果共纳入文献24篇，病例61例。患者平均发病年龄为3.38岁，本病以反复发作的皮肤（57.38%）、口腔黏膜（95.08%）、甲（63.93%）念珠菌感染为特点。信号转导和转录活化子1功能获得性突变（STAT1 gain-of-function，STAT1 GOF）为最常见病因，治疗以唑类药物最常用，复发率高。结论慢性皮肤黏膜念珠菌病是一种少见的免疫缺陷病，临床表现多样，可有多器官和系统的异常，早期诊断和治疗非常重要。

关键词: 慢性皮肤黏膜念珠菌病, 白念珠菌, STAT1

Abstract: Objective This retrospective study aimed to investigate the epidemiology of chronic mucocutaneous candidiasis (CMC), including the causes, clinical features, diagnosis, managements, and outcomes in mainland China between 1980 and 2020. Methods The relevant literatures about chronic mucocutaneous candidiasis in mainland China from 1980 to 2020 were searched in CNKI, Wanfang, Weipu and Pubmed databases and systematically analyzed. Results Retrieving the above databases, a total of 61 patients diagnosed as CMC in mainland China between 1980 and 2020 from 24 reports were found.The mean age of onset was 3.38 years old. CMC is characterized by recurrent infection of the skin(57.38%), oral mucosa(95.08%), and nails(63.93%) by Candida species. CMC can also be accompanied by other infections and autoimmunity. 37 patients received gene test and 23 of them showed STAT1 GOF mutation, which was the most common etiology. The most common treatment for CMC was azole, but still 9.84% of patients died. Conclusion CMC is a rare immunodeficiency disease with various clinical manifestations, including abnormality of multiple organs and systems, which should be considered highly in clinical works.

Key words: chronic mucocutaneous candidiasis, Candida albicans, STAT1 mutation

中图分类号:

R519.3A

骆明芬, 黄欢, 李倩, 刘红芳, 席丽艳. 中国大陆慢性皮肤黏膜念珠菌病回顾性分析(1980—2020年)[J]. 中国真菌学杂志, 2022, 17(5): 368-372,376.

LUO Mingfen, HUANG Huan, LI Qian, XI Liyan, LIU Hongfang. Reprospective analysis of chronic mucocutaneous candidiasis(CMC) in mainland China (1980-2020)[J]. Chinese Journal of Mycology, 2022, 17(5): 368-372,376.

参考文献

[1] OKADA S, ASANO T, MORIYA K, et al. HumanSTAT1 gain-of-function heterozygous mutations:chronic mucocutaneous candidiasis and Type I interferonopathy[J]. J Clin Immunol, 2020,40(8):1065-1081.
[2] 王高松, 周鼎耀. 二性霉素B治疗慢性皮肤粘膜念珠菌病一例报告[J]. 中华皮肤科杂志, 1981,14(2):99-100.
[3] LIU X, HUA H. Oral manifestation of chronic mucocutaneous candidiasis:seven case reports[J]. J Oral Pathol Med, 2007,36(9):528-532.
[4] 朱英华. 慢性皮肤粘膜念珠菌病合并伞枝犁头霉感染1例[A]. 中华中医药学会第九次中医皮肤科学术年会论文集[C].大连:出版社, 2012:64.
[5] 刘光磊, 李成荣, 杨军, 等. STAT1功能获得性基因突变引起的慢性皮肤黏膜念珠菌病1例并文献复习[J]. 中华实用儿科临床杂志, 2016,31(18):1422-1425.
[6] XIANG Q, ZHANG L, LIU X, et al. Autosomal dominant hyper IgE syndrome from a single centre in Chongqing, China (2009-2018)[J]. Scand J Immunol, 2020,91(6):e12885.
[7] 陈征, 李薇, 熊琳, 等. 慢性皮肤黏膜念珠菌病[J]. 临床皮肤科杂志, 2004,33(5):288-289.
[8] 丁艳, 蒙秉新. 婴儿慢性皮肤黏膜念珠菌病合并念珠菌性肠炎1例[J]. 中国麻风皮肤病杂志, 2008,24(10):820-821.
[9] WANG X, ZHANG R, WU W, et al. New and recurrentSTAT1 mutations in seven Chinese patients with chronic mucocutaneous candidiasis[J]. Int J Dermatol, 2017,56(2):e30-e33.
[10] 傅强, 李玉湘, 张秀春, 等. 慢性皮肤黏膜念珠菌病1例[J]. 中国皮肤性病学杂志, 2010(9):852-853.
[11] 田雯, 蒋利萍, 赵晓东. 中国首例STAT1基因突变致常染色体显性遗传慢性皮肤黏膜念珠菌病报道:中华医学会第十七次全国儿科学术大会, 中国河南郑州, 2012[C]:195-196.
[12] 张雅洁, 廉翠红, 刘维达. 婴儿慢性皮肤黏膜念珠菌病一例及实验研究[J]. 中华皮肤科杂志, 2005,24(8):37-39.
[13] 王爱平, 张黎黎, 段周英, 等. 慢性皮肤黏膜念珠菌病1例[J]. 中国真菌学杂志, 2011,6(4):227-229.
[14] 王爱平, 万喆, 涂平, 等. 慢性皮肤黏膜念珠菌病1例[J]. 中国真菌学杂志, 2011,6(6):227-229.
[15] 谷昊, 张蕊, 贺建新, 等. STAT1变异致慢性皮肤黏膜念珠菌病继发免疫性血细胞减少症一例[J]. 中华儿科杂志, 2017,55(7):544-545.
[16] 甘川, 许红梅. 5例STAT1功能获得性基因突变儿童慢性皮肤黏膜念珠菌病临床特点及生化免疫分析[J]. 临床儿科杂志, 2019,37(10):739-743.
[17] 高红. 卡介苗接种异常反应的原发性免疫缺陷病筛查及慢性皮肤黏膜念珠菌病的临床与分子特征研究[D]. 重庆医科大学儿科学, 2018.
[18] DU W, SUN Q, MA D. Generalized, crusted erythematous plaques in a child[J]. Pediatr Dermatol, 2012,29(4):519-520.
[19] 彭一平, 吴志华, 黄文明. 慢性皮肤黏膜念珠菌病一列报告[J]. 中华皮肤科杂志, 1984,17(2):138-139.
[20] 袁建国, 赵爱杰, 许成蓉. 伊曲康唑治疗慢性皮肤黏膜念珠菌病2例[J]. 医药导报, 2012,31(12):1555-1556.
[21] 杨华, 原金凤. 慢性皮肤黏膜念珠菌病一例[J]. 中国麻风皮肤病杂志, 2016,32(12):734-735.
[22] 张林楠, 刘玉峰, 苏淑芳, 等. STAT1变异致慢性皮肤黏膜念珠菌病继发血液系统侵害1例[J]. 中国小儿血液与肿瘤杂志, 2019,24(5):273-274.
[23] LIU J, LEI P. Histopathologic and scanning electron microscope examination of the nail and hair in chronic mucocutaneous candidiasis.[J]. J Am Acad Dermatol, 2003,49(2 Suppl Case Reports):S154-S156.
[24] 江蕾薇, 蒋燕萍, 刘素琴, 等. 慢性皮肤黏膜念珠菌病1例[J]. 中国皮肤性病学杂志, 2010,24(3):269-272.
[25] SHAMRIZ O, TAL Y, TALMON A, et al. Chronic mucocutaneous candidiasis in early life:insights into immune mechanisms and novel targeted therapies[J]. Front Immunol, 2020,11:593289.DOI:10.3389/fimmu.2020.593289.
[26] PATEL D D, KUCHROO V K. Th17 cell oathway in human immunity:lessons from genetics and therapeutic interventions[J]. Immunity, 2015,43(6):1040-1051.
[27] CHEN X, XU Q, LI X, et al. Molecular and phenotypic characterization of nine patients with STAT1 GOF mutations in China[J]. J Clin Immunol, 2020,40(1):82-95.
[28] FIERABRACCI A, ARENA A, TOTO F, et al. Autoimmune polyendocrine syndrome type 1(APECED) in the Indian population:case report and review of a series of 45 patients[J]. J Endocrinol Invest, 2021,44(4):661-677.
[29] BREAK T J, OIKONOMOU V, DUTZAN N, et al. Aberrant type 1 immunity drives susceptibility to mucosal fungal infections[J]. Science, 2021,371(6526):252.
[30] ZHANG W, CHEN X, GAO G, et al. Clinical relevance of gain- and loss-of-function germline mutations in STAT1:a systematic review[J]. Front Immunol, 2021,12:654406.DOI:10.3389/fimmu.2021.654406.
[31] TOUBIANA J, OKADA S, HILLER J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype[J]. BLOOD, 2016,127(25):3154-3164.
[32] PERNIOLA R, FIERABRACCI A, FALORNI A. Autoimmune Addison's disease as part of the autoimmune polyglandular syndrome Type 1:historical overview and current evidence[J]. Front Immunol, 2021,12(606860).
[33] BOISSON-DUPUIS S, KONG X F, OKADA S, et al. Inborn errors of human STAT1:allelic heterogeneity governs the diversity of immunological and infectious phenotypes[J]. Curr Opin Immunol, 2012,24(4):364-378.
[34] CZYRSKI A, RESZTAK M, s' WIDERSKI P, et al. The Overview on the pharmacokinetic and pharmacodynamic interactions of triazoles[J]. Pharmaceutics, 2021,13(11):1961.
[35] PDFIATE Y, HERNANDEZ J,HEMDNEZ-MACHIN B,et al. Therapy with voriconazol for a case of chronic mucocutaneous candidiasis[J].ActasDermosifiliogr,2006,97(10):679-680.
[36] ZIMMERMAN O, ROSLER B, ZERBE C S, et al. Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease[J]. Open Forum Infect Di, 2017,4(4):ofx202.
[37] HIGGINS E, AL SHEHRI T, MCALEER M A, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1(STAT1) mutation[J]. J Allergy Clin Immun, 2015,135(2):356-551.
[38] ROSLER B, WANG X, KEATING S T, et al. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis[J].Clin Exp Immunol, 2018,194(2):205-219.
[39] LEEIDING J W, OKADA S, HAGIN D, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations[J]. J Allergy Clin Immunol, 2018,141(2):704-717.